Financial Snapshot

Revenue
$129.6M
TTM
Gross Margin
92.65%
TTM
Net Earnings
-$134.3M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
542.17%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$237.5M
Q3 2024
Cash
Q3 2024
P/E
-14.69
Nov 29, 2024 EST
Free Cash Flow
-$101.7M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $17.45M $25.82M $57.03M $0.00 $0.00 $0.00
YoY Change -32.42% -54.73%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $17.45M $25.82M $57.03M $0.00 $0.00 $0.00
Cost Of Revenue $1.593M $955.0K $2.075M
Gross Profit $15.85M $24.86M $54.95M
Gross Profit Margin 90.87% 96.3% 96.36%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $108.7M $44.95M $25.40M $8.170M $1.140M $450.0K
YoY Change 141.83% 76.99% 210.86% 616.67% 153.33%
% of Gross Profit 685.63% 180.8% 46.22%
Research & Development $50.31M $42.62M $41.71M $18.83M $3.162M $900.0K
YoY Change 18.04% 2.19% 121.57% 495.38% 251.33%
% of Gross Profit 317.35% 171.45% 75.91%
Depreciation & Amortization $700.0K $300.0K $300.0K $100.0K $37.00K $0.00
YoY Change 133.33% 0.0% 200.0% 170.27%
% of Gross Profit 4.42% 1.21% 0.55%
Operating Expenses $160.6M $88.53M $69.18M $27.00M $4.298M $1.350M
YoY Change 81.42% 27.96% 156.26% 528.15% 218.37%
Operating Profit -$143.2M -$62.71M -$12.16M -$27.00M -$4.298M
YoY Change 128.28% 415.85% -54.97% 528.15%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $3.346M $2.199M $36.00K $188.0K -$40.00K $30.00K
YoY Change 52.16% 6008.33% -80.85% -570.0% -233.33%
% of Operating Profit
Other Income/Expense, Net $7.265M $617.0K -$1.615M $188.0K -$371.0K
YoY Change 1077.47% -138.2% -959.04% -150.67%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$135.9M -$62.10M -$13.77M -$26.81M -$4.670M -$1.320M
YoY Change 118.85% 350.88% -48.63% 474.09% 253.79%
Income Tax $0.00 -$4.000K $55.00K $1.000K $1.000K $0.00
% Of Pretax Income
Net Earnings -$135.9M -$62.09M -$13.83M -$26.81M -$4.670M -$1.319M
YoY Change 118.86% 349.06% -48.43% 474.11% 254.06%
Net Earnings / Revenue -778.89% -240.51% -24.25%
Basic Earnings Per Share -$4.62 -$2.52 -$0.67 -$4.32
Diluted Earnings Per Share -$4.62 -$2.52 -$0.67 -$4.32 -$248.9K -$70.36K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $227.4M $217.0M $171.8M $168.1M $58.00M $2.400M
YoY Change 4.8% 26.31% 2.21% 189.83% 2316.67%
Cash & Equivalents $224.9M $71.66M $171.3M $168.1M $58.00M $2.400M
Short-Term Investments $2.495M $145.4M $483.0K
Other Short-Term Assets $7.868M $4.767M $4.045M $2.500M $0.00 $0.00
YoY Change 65.05% 17.85% 61.8%
Inventory $3.107M
Prepaid Expenses
Receivables $16.62M
Other Receivables $1.093M
Total Short-Term Assets $256.1M $225.4M $176.0M $170.7M $58.00M $2.400M
YoY Change 13.65% 28.09% 3.08% 194.31% 2316.67%
Property, Plant & Equipment $3.348M $1.532M $1.829M $1.200M $300.0K $0.00
YoY Change 118.54% -16.24% 52.42% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $631.0K $371.0K
YoY Change 70.08%
Other Assets $1.514M $585.0K $1.126M $100.0K $0.00 $0.00
YoY Change 158.8% -48.05% 1026.0%
Total Long-Term Assets $9.360M $2.488M $2.955M $1.300M $300.0K $0.00
YoY Change 276.21% -15.8% 127.31% 333.33%
Total Assets $265.5M $227.9M $178.9M $172.0M $58.30M $2.400M
YoY Change
Accounts Payable $18.15M $9.910M $2.856M $2.200M $500.0K $200.0K
YoY Change 83.14% 246.99% 29.82% 340.0% 150.0%
Accrued Expenses $18.79M $5.519M $7.870M $3.200M $400.0K $0.00
YoY Change 240.41% -29.87% 145.94% 700.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.94M $15.43M $11.48M $5.400M $800.0K $200.0K
YoY Change 139.39% 34.42% 112.56% 575.0% 300.0%
Long-Term Debt $29.82M $19.43M $0.00 $0.00 $0.00 $0.00
YoY Change 53.44%
Other Long-Term Liabilities $1.748M $100.0K $699.0K $600.0K $100.0K $0.00
YoY Change 1648.0% -85.69% 16.5% 500.0%
Total Long-Term Liabilities $31.57M $19.53M $699.0K $600.0K $100.0K $0.00
YoY Change 61.6% 2694.56% 16.5% 500.0%
Total Liabilities $68.50M $34.96M $12.18M $6.000M $900.0K $200.0K
YoY Change 95.93% 187.12% 102.95% 566.67% 350.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 29.38M shares 24.62M shares 20.55M shares 6.207M shares
Diluted Shares Outstanding 29.38M shares 24.62M shares 20.55M shares 6.207M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $1.974 Billion

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 244 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Industry: Biological Products, (No Diagnostic Substances) Peers: Bakhu Holdings, Corp. Cara Therapeutics, Inc. Esperion Therapeutics, Inc. Evolus, Inc. Fulcrum Therapeutics, Inc. OCULAR THERAPEUTIX, INC JOHNSON & JOHNSON Nuvation Bio Inc. Phathom Pharmaceuticals, Inc. Rani Therapeutics Holdings, Inc.